ArQule Initiates Phase I/II Trial for Lung Cancer Drug
Posted on: Friday, 14 March 2008, 06:00 CDT
ArQule has started patient dosing in a Phase I/II clinical trial program of ARQ 197, administered in combination with erlotinib in patients with advanced non-small cell lung cancer.
The non-small cell lung cancer (NSCLC) program consists of two trials. The first is a Phase I trial in which investigators will determine the safety, tolerability and a recommended Phase II dose of ARQ 197 when administered in combination with erlotinib in this patient population. Secondarily, investigators will evaluate the pharmacokinetic profile and assess the preliminary anti-tumor activity of this combination therapy.
Pending the completion of Phase I, the company plans to initiate a Phase II trial, designed as a multi-center, placebo controlled, randomized trial comparing ARQ 197 plus Tarceva against placebo plus Tarceva.
Peter Lawrence, COO of ArQule, said: "The high level of interest in this particular indication within the oncology community has been generated by scientific data showing that the development of resistance in NSCLC tumors to therapy with EGFR (epidermal growth factor receptor) inhibitors may be linked to an increase in c-Met signaling. Overcoming such resistance has been a challenge, and we believe the inhibition of c-Met may offer a new strategy in treating these tumors and extending the lives of patients."
Source: Datamonitor
Related Articles
- Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)
- Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
- AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer
- Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
- ArQule Announces Initiation of Two Phase 2 Trials With C-Met Inhibitor, ARQ 197
- ProEthic Pharmaceuticals Announces Positive Phase I Trial Results for Fast-Acting Acute Pain Product Candidate; Trials Confirm Strong Pharmacokinetic Profile of PRO-571
- CV Therapeutics Completes Enrollment of Second Regadenoson Phase 3 Trial
- Schering Begins Phase 2 Trials of ZK-EPO
- Biolex's Locteron Safe in Phase 1 Trial
- Cell Genesys Reports Encouraging Follow Up Clinical Data From Phase 2 Trial of GVAX(R) Leukemia Vaccine
 |
 |
User Comments (0)
RSS Feeds